Biodesix (BDSX) investor relations material

Company overview and business model

• Specializes in diagnostic solutions, focusing on improving clinical care and outcomes using a multi-omic approach to develop blood-based lung cancer diagnostic tests and provide development services to biopharmaceutical and life sciences companies.

• Revenue streams include diagnostic testing for healthcare providers and development services for industry clients and academic partners, with five commercial blood-based lung diagnostic tests and custom test development capabilities.

• Offers end-to-end diagnostic solutions, including translational research, biomarker discovery, assay design, validation, regulatory, reimbursement, commercialization, and logistical support.

• Continuously integrates new technologies to expand service and product offerings, leveraging partnerships to enhance knowledge and adapt to evolving clinical and regulatory landscapes.

Financial performance and metrics

• Qualifies as a "smaller reporting company" under SEC rules, allowing for scaled disclosures due to market cap and revenue thresholds.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by the selling stockholder; proceeds from any cash exercise of warrants will be used for working capital and general corporate purposes.